182 related articles for article (PubMed ID: 29193658)
1. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
[TBL] [Abstract][Full Text] [Related]
2. Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Mimoto R; Imawari Y; Hirooka S; Takeyama H; Yoshida K
Oncogene; 2017 Mar; 36(13):1862-1872. PubMed ID: 27721402
[TBL] [Abstract][Full Text] [Related]
3. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract][Full Text] [Related]
4. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Mimoto R; Taira N; Takahashi H; Yamaguchi T; Okabe M; Uchida K; Miki Y; Yoshida K
Cancer Lett; 2013 Oct; 339(2):214-25. PubMed ID: 23791882
[TBL] [Abstract][Full Text] [Related]
5. Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Yan H; Hu K; Wu W; Li Y; Tian H; Chu Z; Koeffler HP; Yin D
PLoS One; 2016; 11(8):e0159954. PubMed ID: 27532268
[TBL] [Abstract][Full Text] [Related]
6. Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Ito D; Yogosawa S; Mimoto R; Hirooka S; Horiuchi T; Eto K; Yanaga K; Yoshida K
Cancer Sci; 2017 Aug; 108(8):1565-1573. PubMed ID: 28502078
[TBL] [Abstract][Full Text] [Related]
7. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Yokoyama-Mashima S; Yogosawa S; Kanegae Y; Hirooka S; Yoshida S; Horiuchi T; Ohashi T; Yanaga K; Saruta M; Oikawa T; Yoshida K
Cancer Lett; 2019 Jun; 451():100-109. PubMed ID: 30851422
[TBL] [Abstract][Full Text] [Related]
8. Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Kumamoto T; Yamada K; Yoshida S; Aoki K; Hirooka S; Eto K; Yanaga K; Yoshida K
Int J Oncol; 2020 Jun; 56(6):1529-1539. PubMed ID: 32236621
[TBL] [Abstract][Full Text] [Related]
9. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
10. Dual-specificity tyrosine-regulated kinase 2 exerts anti-tumor effects by induction of G1 arrest in lung adenocarcinoma.
Harada E; Yoshida S; Imaizumi Y; Kawamura A; Ohtsuka T; Yoshida K
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130600. PubMed ID: 38508285
[TBL] [Abstract][Full Text] [Related]
11. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Taira N; Mimoto R; Kurata M; Yamaguchi T; Kitagawa M; Miki Y; Yoshida K
J Clin Invest; 2012 Mar; 122(3):859-72. PubMed ID: 22307329
[TBL] [Abstract][Full Text] [Related]
12. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
Hua K; Jin J; Zhao J; Song J; Song H; Li D; Maskey N; Zhao B; Wu C; Xu H; Fang L
Int J Oncol; 2016 May; 48(5):1997-2006. PubMed ID: 26934863
[TBL] [Abstract][Full Text] [Related]
13. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
[TBL] [Abstract][Full Text] [Related]
14. Enforced dual-specificity tyrosine-regulated kinase 2 expression by adenovirus-mediated gene transfer inhibits tumor growth and metastasis of colorectal cancer.
Imaizumi Y; Yoshida S; Kanegae Y; Eto K; Yoshida K
Cancer Sci; 2022 Mar; 113(3):960-970. PubMed ID: 34932844
[TBL] [Abstract][Full Text] [Related]
15. miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14.
Ji Q; Xu X; Li L; Goodman SB; Bi W; Xu M; Xu Y; Fan Z; Maloney WJ; Ye Q; Wang Y
Cell Death Dis; 2017 Oct; 8(10):e3103. PubMed ID: 29022909
[TBL] [Abstract][Full Text] [Related]
16. Multiple functions of DYRK2 in cancer and tissue development.
Yoshida S; Yoshida K
FEBS Lett; 2019 Nov; 593(21):2953-2965. PubMed ID: 31505048
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway.
Ou-Yang J; Huang LH; Sun XX
Gynecol Obstet Invest; 2017; 82(3):230-239. PubMed ID: 27505004
[TBL] [Abstract][Full Text] [Related]
18. Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Gu X; Wang Y; Wang H; Ni Q; Zhang C; Zhu J; Huang W; Xu P; Mao G; Yang S
Med Oncol; 2015 Jul; 32(7):195. PubMed ID: 26033031
[TBL] [Abstract][Full Text] [Related]
19. miR-455 inhibits breast cancer cell proliferation through targeting CDK14.
Wang B; Zou A; Ma L; Chen X; Wang L; Zeng X; Tan T
Eur J Pharmacol; 2017 Jul; 807():138-143. PubMed ID: 28300591
[TBL] [Abstract][Full Text] [Related]
20. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
